This cell line was chosen to accurately replicate the effects of the PPAT-EVs within a relevant biological context, as all our PPAT samples originate from androgen-sensitive tumours, and 22Rv1 cells derive from a primary prostate tumour and possess the androgen receptor. The gene discussed is AR; the disease is neoplasm.